Kyverna Therapeutics, Inc.
NASDAQ:KYTXBiotechnology
-$0.12 today
- Market cap
- $283.23M
- Beta
- 1.96
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.59
Volume 1.05M
Average 0.94M
KYTX Total Debt
Short-term and long-term borrowings combined.
Kyverna Therapeutics, Inc.NASDAQ: KYTX
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt rises 386.5% from a year ago
Total debt stood at $33.76M at the end of Q1 FY2026, up 386.5% from a year earlier and up 16.3% from the prior quarter. Over 3 fiscal years it compounded at +40.1% a year.
Context
- Total debt amounted to 13.1% of total assets at the end of Q1 FY2026, up 10.5 pp from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +386.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 29.03M USD
- Year-over-year change
- +252.2%
- 4-year CAGR
- +51.2%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.03M | +252.2% |
| FY2024 | 2024-12-31 | 8.24M | -9.2% |
| FY2023 | 2023-12-31 | 9.08M | -14.1% |
| FY2022 | 2022-12-31 | 10.56M | +90.2% |
| FY2021 | 2021-12-31 | 5.56M | — |
Total Debt vs competitors
How KYTX compares with its peers on the latest reported figures
- KYTX's Mar 2026 total debt of $33.76M is the 4th highest of the 11 companies compared; the peer median is $14.24M.
- Its year-over-year change of +386.5% is the highest of 11, against a peer median of -4.2%.
- Total debt amounts to 13.1% of total assets for KYTX, versus a peer median of 4.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $81.05M | -0.3% | -6.3% | 20.5% | |
| Mar 2026 | $71.97M | +131.2% | +20.4% | 48.2% | |
| Mar 2026 | $48.85M | -14.4% | -9.0% | 13.9% | |
| Mar 2026 | $33.76M | +386.5% | +40.1% | 13.1% | |
| Mar 2026 | $26.45M | -8.1% | +74.1% | 17.9% | |
| Mar 2026 | $21.12M | +356.7% | +44.6% | 6.5% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $7.37M | -21.6% | -16.4% | 2.9% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $6.95M | +15.9% | +12.1% | 2.7% |
| Mar 2026 | $634K | -56.1% | -35.4% | 0.2% | |
| Mar 2026 | $136K | +126.7% | -28.9% | 0.1% | |
| Mar 2026 | $0 | -100.0% | -76.4% | 0.0% | |
| Peer median (excluding KYTX) | $14.24M | -4.2% | -7.6% | 4.7% | |
Competitors are the stored peer set for KYTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 76.07M | 37.74M | 34.65M | 96.62M | 124.09M |
| Short-term Investments | 0 | 13.59M | 22.9M | 189.36M | 155.16M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.02M | 1.93M | 3.12M | 4.62M | 3.7M |
| Total Current Assets | 77.09M | 53.25M | 60.66M | 290.6M | 282.95M |
| Property, Plant & Equipment (Net) | 7.81M | 12.44M | 10.61M | 10.66M | 5.42M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 593K | 1.23M | 3.92M | 5.26M | 5.45M |
| Total Non-current Assets | 8.4M | 13.67M | 14.53M | 15.92M | 10.87M |
| Total Assets | 85.49M | 66.92M | 75.2M | 304.65M | 293.83M |
| Account Payables | 773K | 1.45M | 4.36M | 4.62M | 5.31M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 6M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.72M | 565K | 9.77M | 4.88M | 9.99M |
| Total Current Liabilities | 15.93M | 11.95M | 19.86M | 33.76M | 36.49M |
| Long-term Debt | 0 | 0 | 0 | 0 | 24.74M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 1.03M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 110.05M | 6K | 0 | 0 | 0 |
| Total Non-current Liabilities | 115.81M | 8.29M | 6.16M | 4.3M | 25.06M |
| Total Liabilities | 131.74M | 20.25M | 26.02M | 38.06M | 61.55M |
| Common Stock | 0 | 0 | 0 | 0 | 1K |
| Retained Earnings | (46.78M) | (75.68M) | (136.04M) | (263.52M) | (424.83M) |
| Accumulated OCI | 0 | (26K) | 4K | 105K | 97K |
| Other Stockholders Equity | 0 | (0) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (46.25M) | 46.68M | 49.18M | 266.59M | 232.28M |
| Total Debt | 5.56M | 10.56M | 9.08M | 8.24M | 29.03M |
| Net Debt | (70.51M) | (27.17M) | (25.57M) | (88.38M) | (95.06M) |
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
Intrinsic Alpha fair value
Locked
Current Price
$4.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.